Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a randomized controlled trial of different glycemic targets during tratment of women with GDM with assessement of epygenetic aspects of their effects on the fetus and pregnancy outcomes. This study is interventional, randomised controlled trial, open-label.
The study aims to clarify the effect of hyperglycemia and its correction, the level of physical activity and consumption of major macro- and micronutrients by women during pregnancy on DNA methylation and expression of genes involved in neuroendocrine regulation and development of metabolic diseases in offspring, as well as functional characteristics of human umbilical vein endothelial cells (HUVECs). For the purpose of the study women with GDM are randomised to 2 treatment groups per glycemic targets ( very tight and tight-moderate glycemic targets). Data on glycenmic levels during the study and consumption of major macro- and micronutrients will be collected using a mobile application with electronic dairies report forms.
This clinical trial record primarily describes the overarching observational cohort study "Genetic and Epigenetic Mechanisms of Developing Gestational Diabetes Mellitus and Its Effects on the Fetus" including women with GDM and healthy pregnant women.
Substudy Protocol: A key predefined component of this larger study is an interventional, randomized controlled substudy entitled "Tight versus less tight glycaemic targets for women with gestational diabetes mellitus: a randomised controlled trial" (also known as the GEM GDM Trial).
The GEM GDM Trial is an open-label, randomized controlled trial (RCT) that compares the effects of tight (very tight) versus less tight (tight-moderate) glycemic control on maternal and neonatal outcomes in women diagnosed with Gestational Diabetes Mellitus (GDM). Participants from the main GEM cohort who are diagnosed with GDM according to International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria are eligible for screening and subsequent randomization into this substudy.
The substudy aims to enroll 650 pregnant women with a singleton pregnancy and GDM, randomly assigning them in a 1:1 ratio to one of two glycemic target groups.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| very tight glycemic targets | Active Comparator |
| |
| tight-moderate glycemic targets | Active Comparator | Less tight glycemic targets |
|
| Control group | No Intervention | Only observation in women with normal glucose tolerance |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Very tight glycemic targets, life-style modification, insulin therapy if needed | Other | All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (<5.1 mmol/L fasting and <7.0 mmol/L postprandial) are not achieved insulin therapy is started |
| Measure | Description | Time Frame |
|---|---|---|
| LGA newborns | Number (%) of large for gestational age (LGA) newborns | within 24 hours after delivery |
| TRIB1 | Level of expression of TRIB1 gene | within 24 hours after delivery |
| LEP | Level of expression of LEP gene | within 24 hours after delivery |
| ADIPOQ | Level of expression of ADIPOQ gene | within 24 hours after delivery |
| ANGPTL4 | Level of expression of ANGPTL4 gene | within 24 hours after delivery |
| NR3C1 | Level of expression of NR3C1 gene | within 24 hours after delivery |
| Measure | Description | Time Frame |
|---|---|---|
| Cesarian sections | Number (%) of deliveries by Cesarian sections | within 24 hours after delivery |
| SGA newborns | Number (%) of small for gestationa age (SGA) newborns |
| Measure | Description | Time Frame |
|---|---|---|
| HbA1c | HbA1c level, % | 36 week |
| fasting glucose | fasting plasma glucose level, mmol/L | 36 week |
Inclusion Criteria:
Exclusion Criteria:
Gestation
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Griniva Elena, MD, PhD | Almazov NMRC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Almazov NMRC | Saint Petersburg | 197341 | Russia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37815094 | Derived | Hofer OJ, Martis R, Alsweiler J, Crowther CA. Different intensities of glycaemic control for women with gestational diabetes mellitus. Cochrane Database Syst Rev. 2023 Oct 10;10(10):CD011624. doi: 10.1002/14651858.CD011624.pub3. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Women with GDM are randomised to 2 treatment groups: group 1 - treatment group with very tight glycemic targets (<5.1 mmol / L fasting glucose and <7.0 mmol / l hour after a meal) and group 2 - treatment group with tight-moderate glycemic targets (<5.3 mmol / L fasting glucose and <7.8 mmol / l in an hour after a meal).
Not provided
Not provided
Not provided
Not provided
|
|
| Tight-moderate glycemic targets, life-style modification, insulin therapy if needed | Other | All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (<5.3 mmol/L fasting and <7.8 mmol/L postprandial) are not achieved insulin therapy is started |
|
| within 24 hours after delivery |
| Methylation of candidate genes | Levels of methylation (%) of candidate genes with confirmed differences in the expression in HUVECs isolated within 24 hours after delivery | within 24 hours after delivery |
| rate of macrosomia | birth weight ≥4000 g | delivery |
| birthweight | birth weight (g) | delivery |
| length at birth | length at birth (cm) | delivery |
| rate of stillbirth | Foetal death in utero > 20 weeks | > 20 weeks |
| rate of neonatal death | death <1 months after delivery | 1 month after delivery |
| rate of shoulder dystocia | vaginal cephalic delivery in which, after the head is delivered and gentle traction proves unsuccessful, additional obstetric maneuvers are required to complete the delivery of the fetus | delivery |
| rate of birth trauma | bone fracture, damage to nerves | delivery |
| rate of preterm birth | babies born at <37 weeks gestational age | delivery |
| gestational age | gestational age at delivery | delivery |
| rate of neonatal hypoglycemia | plasma glucose level below 2.6 mmol/L within the first 48 hours of age | first 48 hours of age |
| rate of neonatal respiratory distress syndrome | respiratory failure or distress | delivery |
| rate of jaundice | jaundice necessitating phototherapy and/or exchange transfusion | delivery |
| Rate of neonates with Apgar score <7 at 5 minutes | A measure of the health of a newborn infant done at 5 min. The newborn is given points (0, 1, 2) for heart rate, respiratory effort, muscle tone, response to stimulation and skin coloration. A score of 10 points indicates excellent health. | delivery |
| rate of NICU admission | neonatal intensive care unit (NICU) admission | within 72 hours postpartum |
| length of stay of infants admitted to neonatal intensive care unit | length of stay of infants admitted to neonatal intensive care unit, days | up to 30 days after delivery |
| cord blood C-peptide | cord blood C-peptide levels | delivery |
| rate of composite neonatal outcome | infant death, shoulder dystocia, bone fracture, and nerve palsy | delivery |
| rate of maternal death | death of a woman while pregnant or within 42 days of termination of pregnancy | within 42 days of termination of pregnancy |
| rate of eclampsia | generalized convulsions and/or coma | from 20 weeks to delivery |
| rate of placental abruption | premature separation of the placenta from the uterine wall before delivery | before delivery |
| rate of postpartum hemorrhage | requiring or offered blood transfusion or an operative procedure | delivery |
| rate of preeclampsia | onset of new hypertension and proteinuria and/or end-organ dysfunction after 20 weeks of gestation | from 20 weeks to delivery |
| rate of gestational hypertension | new-onset hypertension (140/90 mmHg or higher), without proteinuria after 20 weeks of gestation | from 20 weeks to delivery |
| rate of induction of labor | the use of medications or other methods to bring on (induce) labour | delivery |
| rate of perineal trauma | perineal or deep vaginal laceration | delivery |
| rate of operative vaginal delivery (vacuum extraction) | application of vacuum to the foetal head | delivery |
| gestational weight gain | Weight from preconception until last weight measured within 4 weeks before delivery. | delivery |
| blood pressure at admission to the birth unit | blood pressure at admission to the birth unit, mm Hg | at admission to the birth unit |
| rate of maternal hypoglycemia | typical symptoms with capillary glucose <3.9 mmol/L, or, if asymptomatic, by capillary glucose <3.3 mmol/L | during pregnancy |
| insulin therapy requirements | Prescription of insulin treatment | from 12 weeks to delivery |
| rate of stroke | Maternal sudden loss of brain function due to blocked or burst blood vessels during pregnancy or postpartum. | during pregnancy or within 42 days after delivery |
| rate of acute pulmonary oedema | Maternal acute pulmonary oedema | During pregnancy of within 42 days after delivery |
| rate of cardiac arrest | Maternal cardiac arrest | During pregnancy or within 42 days after delivery |
| rate of maternal respiratory arrest | During pregnancy or within 42 days after delivery |
| rate of maternal respiratory distress syndrome | During pregnancy or within 42 days after delivery |
| rate of maternal deep vein thrombosis or pulmonary embolus requiring anticoagulant therapy | During pregnancy or within 42 days after delivery |
| rate of maternal haemolysis | During pregnancy or within 42 days after delivery |
| lipid profile | levels of serum total cholesterol, low density lipoproteins, high density lipoproteins , triglycerides, mmol/L | 36 week |
| glycaemic control parameters | mean fasting and postprandial capillary glucose, adherence to target ranges via self-monitoring | from 12 weeks to delivery |
| ID | Term |
|---|---|
| D016640 | Diabetes, Gestational |
| ID | Term |
|---|---|
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided